BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. The lysophosphatidic acid receptor 1 (LPA 1 ) pathway is implicated in IPF etiology. Safety and efficacy of BMS-986020, a high-affinity LPA 1 antagonist, was assessed vs placebo in a phase 2 study in patients with IPF.
Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing lung disease that leads to irreversible loss of lung function. 1 IPF has a median survival of 3 to 5 years, 2 and the 5-year mortality rate is between 60% and 80%. 3 The incidence of IPF in the United States is estimated to be between two and 29 cases per 100,000 persons, affecting men more frequently than women. 1 Only two therapies, pirfenidone (unknown mechanism of action) and nintedanib (a tyrosine kinase inhibitor), are approved for the treatment of IPF in the United States. 2, 4 Both treatments slow decline in FVC. A pooled analysis showed that patients who received pirfenidone had a decreased risk of nonelective respiratory-related hospitalizations over the course of 1 year, 5 and patients who received nintedanib had modest gains in quality of life. 6 Nonetheless, there is a continued need for novel therapeutic approaches that halt or reverse fibrosis.
The pathogenesis of IPF is characterized by an aberrant wound-healing response. 7 In patients with IPF, fibroblasts migrate to the fibrin-rich exudates that develop in the airspaces of the lung after injury; the extent of this migration generally corresponds with IPF symptom severity. 7 Lysophosphatidic acid receptor 1 (LPA 1 ) has been implicated in the development of IPF given its role in mediation of fibroblast recruitment, vascular leak, and endothelial barrier dysfunction in animal models. 7 In the bleomycin mouse model of pulmonary fibrosis, for example, LPA 1 -deficient mice showed reduced levels of fibroblast recruitment and decreased vascular permeability, indicating a protective role for decreased lysophosphatidic acid (LPA) signaling. 7 Furthermore, levels of the LPA are elevated in BAL samples of patients with IPF, 7 supporting the clinical relevance of this signaling pathway in IPF development.
BMS-986020 is a high-affinity small-molecule antagonist of LPA 1 . Here we present the results of a phase 2 study designed to assess the safety and efficacy of once daily (qd) or bid 600 mg BMS-986020 compared with placebo for 26 weeks in patients with IPF.
Methods

Patients
Eligible patients were between the ages of 40 and 90 years, had a confirmed diagnosis of IPF prior to screening, had a predicted postbronchodilator FVC between 45% and 90%, had a diffusing capacity for carbon monoxide (DLCO) between 30% and 80% (adjusted for hemoglobin and altitude), had an extent of fibrosis greater than emphysema on high-resolution CT (HRCT) scan, had a < 10% change in postbronchodilator FVC between screening and day 1, were able to walk $ 150 m during screening of the 6-min walk test, and had a demonstrated fall of $ 2% in oxygen saturation on exertion during a screening walk test. Patients with prior use of pirfenidone or nintedanib for # 3 months in the previous 12 months were permitted to participate in the study after a 4-week washout period. Patients were excluded from the study if they experienced significant worsening of IPF during the screening process, had a FEV 1 /FVC ratio of < 0.8 after bronchodilator administration, had a history of clinically significant exposure known to cause or provide an explanation for fibrosing lung disease, had clinically significant asthma or COPD, had smoked cigarettes within 4 weeks of screening or were unwilling to avoid tobacco products throughout the study, or had abnormal laboratory findings. More detailed criteria are provided in the e-Appendix 1.
Study Design and Procedures
Study IM136003 was a phase 2, multiple-dose, three-group, parallelarm, multicenter, randomized, double-blind, placebo-controlled trial that evaluated the efficacy and safety of 600 mg qd or bid BMS-986020 for 26 weeks in patients with IPF. The original enrollment target of 300 participants was lowered to include a minimum of 135 participants after slow enrollment after the approval of pirfenidone and nintedanib for the treatment of IPF in the United States; the site network was expanded to include ex-US locations with no approved treatments. Patients were randomized in a 1:1:1 ratio to one of three treatment arms: placebo, BMS-986020 600 mg qd, or BMS-986020 600 mg bid. A study coordinator employed by the sponsor randomly allocated eligible patients to treatments arms and assigned sequential patient numbers using a computer-generated randomization scheme. Patients, investigators, and the sponsor were blinded with the exception of the following staff: bioanalytical staff, a single pharmacokineticist, designated pharmacokinetics programmers, a single biostatistician, and a statistical programmer (to provide data analyses to the data monitoring committee for ongoing safety analysis).
The study was conducted in accordance with Good Clinical Practice and the Declaration of Helsinki. A data monitoring committee provided study oversight. All patients provided written informed consent prior to enrollment. The study protocol, amendments, and informed consent received appropriate approval by the institutional review board/independent ethics committee prior to the initiation of the study. A complete list of each institutional review board is provided in e- Table 1 . The study was coordinated by the Duke Clinical Research Institute.
Study End Points
The primary end point was the rate of change in FVC from baseline to week 26 in patients with IPF randomized to receive 600 mg BMS-986020 qd or bid vs placebo. Secondary end points included safety and tolerability evaluations, assessments of the treatment effect from baseline to week 26 on the quantitative lung fibrosis (QLF) score on HRCT scan, change in 6-min walk distance, DLCO, and dyspnea. A post hoc analysis evaluated the impact of treatment on blood biomarkers.
Study Assessments
Adverse events (AEs) were monitored throughout the study. 
Statistical Methods
The revised enrollment was $ 135 patients total with $ 45 patients in each treatment group. The primary end point was assessed using a mixed model for a repeated-measures approach with no multiple comparison adjustments for multiple doses. A multiple-imputation sensitivity analysis was used to address the impact of missing data on the rate of change in FVC. QLF was analyzed using an analysis of variance approach with log-transformed data adjusted for age, sex, height, and baseline score. Dyspnea was measured by the UCSD SOBQ at baseline, day 28, and weeks 13 and 26; increases in the UCSD SOBQ indicated a worsening of dyspnea. The SF-36 was provided to patients at baseline, day 28, week 13, and week 26 and assessed changes from baseline in patient quality of life. Time to death or nonelective hospitalization was defined as the elapsed time in days from randomization to the first nonelective hospitalization or death. In an a priori power calculation assuming 45 participants per treatment arm, assuming an SD of 0.25 L in the FVC change from baseline to week 26, and if the true treatment effect size was a difference of 0.1 L, there was a 50% chance to observe a mean treatment difference > 0.1 L, a 74% chance to observe a mean treatment difference of > 0.06 L, and a 94% chance to observe a mean treatment difference > 0 L.
The enrolled population included all patients who signed informed consent. The intent-to-treat population was defined as all patients who were randomized to treatment. The safety population was defined as all enrolled patients who received at least one dose of the study drug.
Results
Patients
This study was conducted at 52 sites (United States: 30; Mexico: 6; Australia: 5; Chile: 4; Peru: 4; Columbia: 3) between April 2013 and February 2016. Of 325 patients who provided informed consent, 143 were randomized and 108 completed the 26-week dosing phase (Fig 1) . Of the 35 patients who discontinued the trial prematurely, 13 patients discontinued because of AEs and 10 patients (noted as physician decision) discontinued after the sponsor decision to stop the study because of concerns regarding potential gallbladder toxicity noted in three patients.
There were no meaningful differences in baseline demographics or clinical characteristics between the treatment arms. Most patients were white (71%) and men The study was terminated early, and the last 10 patients were withdrawn after the sponsor's decision to stop the study because of concerns regarding potential gallbladder toxicity noted in three patients.
chestjournal.org (71%); 37 patients (26%) had biopsy-confirmed IPF at baseline, and the median FVC value was 2.46 L (range, 1.15-4.25 L) ( Table 1) . A greater percentage of patients enrolled in the BMS-986020 qd group had a history of smoking (75%) compared with the bid group (52%) or the placebo group (53%). The median duration of smoking was similar between the treatment groups (23, 24, and 23 years in the qd, bid, and placebo groups, respectively).
FVC
In all three treatment groups, a decline in mean FVC was observed across all visits (Fig 2, Table 2 ). At week 26, patients treated with BMS-986020 600 mg bid experienced a significantly slower rate of decline in FVC compared with placebo (P ¼ .049) ( Table 2 ). The differences in FVC changes between the 600 mg qd and placebo groups were not significant. Of the patients treated with BMS-986020 qd and bid, 38% and 37%, respectively, experienced no decline in FVC compared with 18% of placebo-treated patients (Table 3) .
QLF, DLCO, 6-Min Walk Test, Dyspnea, and Quality of Life No significant differences in mean change from baseline to week 26 in QLF on HRCT scan, dyspnea, or DLCO were observed between either BMS-986020 group and patients who received placebo (Fig 3) . Overall, the results of the 6-min walk test were highly variable because of inconsistencies in implementation (data not shown). There were no significant differences between treatment groups in the mean changes from baseline to week 26 in the UCSD SOBQ scores (Table 4) . In all treatment groups, mean changes from baseline in the aggregate physical and mental scores on the SF-36 were small; no significant differences were observed in either active treatment arm compared with placebo (data not shown).
Exploratory Biomarkers
Seventy-one biomarkers were analyzed at baseline, day 28, and week 26. Patients who received BMS-986020 qd or bid experienced increases in adiponectin and decreases in C3M, a type III collagen degradation marker that has been reported to be elevated in patients with IPF, vs patients who received placebo (Fig 4) .
Safety Outcomes
A total of 116 patients (81%) experienced AEs during the study and the 4-week follow-up safety assessment period (Table 5 ). Of the AEs that occurred at an incidence of $ 10% in any treatment group, arthralgia and increased blood alkaline phosphatase (ALP) appeared to be dose related. More patients in the BMS-986020 bid group had elevations in alanine aminotransferase, aspartate aminotransferase, and ALP vs the qd or placebo groups. However, none had evidence of drug-induced liver toxicity based on the criteria of Hy's law (ie, elevations in liver enzymes three or more times upper limit of normal, total bilirubin more than two times upper limit of normal, little or no cholestasis, no valid explanation for liver injury), 8 and all increases in liver function tests resolved to baseline levels after discontinuation of BMS-986020.
A total of three patients experienced serious adverse events (SAEs) consistent with cholecystitis along with elevations in liver enzymes that led to study termination. Unblinding revealed that these three patients were treated with BMS-986020 qd or bid and had experienced four SAEs that required prolonged hospitalization. One patient in the qd group had an SAE of severe gallstone pancreatitis, and two patients in the bid group had three SAEs that included hydrocholecystitis, gallbladder necrosis, and/or gallbladder perforation. These SAEs were assessed as being related to BMS-986020 treatment. Five patients died during the study; all deaths were considered related to IPF.
No clinically relevant ECG differences were observed. Six patients in the placebo group and four patients in the BMS-986020 qd group with an AE of overdose See Table 1 legend for expansion of abbreviation. changes in mean in QLF, dyspnea, and DLCO were observed with BMS-986020 treatment compared with placebo. Results from the 6-min walk test were of limited interpretability because of a methodology change regarding the use of supplemental oxygen and the inability to track whether the change was implemented. Data were pooled from all patients regardless of whether their tests occurred before or after the methodology change, likely contributing to the observed variability in the results. Collectively, these results are suggestive that LPA antagonism could have a benefit in treatment of IPF disease progression.
Several biomarkers of fibrosis or inflammation were improved in patients treated with BMS-986020 vs placebo. Levels of C3M, a type III collagen degradation marker, were decreased in patients treated with BMS-986020. The Prospective Study of Fibrosis in the Lung Endpoints (PROFILE) study found that patients with progressive IPF had higher levels of C3M compared with healthy individuals or patients with stable disease. 9 Increases in adiponectin levels were also observed in patients treated with BMS-986020. Decreased adiponectin levels have been observed in patients with IPF, 10 and pretreatment with adiponectin has been shown to reduce fibrosis in preclinical models of lung fibrosis. 11 These data should be interpreted with caution because of the low number of patients with available biomarker data.
BMS-986020 600 mg qd and bid were well tolerated in most patients; however, dose-related increases in liver enzymes were observed in several patients and there were three cases of cholecystitis that resulted in cholecystectomy and led to the early termination of the trial. Similar safety issues were not observed in a chestjournal.org previous phase 1 study because participants were healthy and their exposure to BMS-986020 was short term. In contrast, patients in this phase 2 study were older, had IPF and multiple comorbidities, and received BMS-986020 for a longer duration; the events that resulted in study termination were not detected until after patients received 4 months of treatment. Studies comparing BMS-986020 with BMS-986234, a structurally distinct LPA 1 antagonist, suggest that these SAEs were likely offtarget effects unique to BMS-986020 related to inhibition of hepatobiliary transporters and bile composition. 12 The strength of the study was the prospective, randomized trial design; however, there were several limitations. Although originally intended as a US study, the approval of pirfenidone and nintedanib for the treatment of IPF dramatically affected the ability to enroll patients in the United States, prompting a shift to a smaller sample size and the inclusion of sites outside the United States, resulting in more patient heterogeneity; these changes may limit data generalizability. Finally, given that the concomitant use of pirfenidone and/or nintedanib was prohibited, the effect of concomitant treatment with BMS-986020 is unknown. Six patients in the placebo group and four patients in the BMS-986020 qd group with an SAE of overdose continued taking the study drug for 23 to 34 days after week 26 when the study sites erroneously returned medication to the patients at the week 26 compliance visit; one patient in the BMS-986020 bid group had a confirmed overdose, having accidentally taken two additional tablets on 1 day.
b
One patient had a treatment-related SAE of severe gallstone pancreatitis.
c Three patients had four treatment-related SAEs (hydrocholecystitis, gallbladder necrosis, gallbladder perforation, and pulmonary hypertension). In conclusion, patients with IPF treated with BMS-986020 600 mg bid exhibited significantly slower rates of decline from baseline to 26 weeks vs placebo. Although both dose regimens of BMS-986020 were well tolerated in most patients, they were associated with presumed hepatobiliary toxicity as manifested by dose-related elevations in hepatic transaminases and ALP in some patients, and treatment-related SAEs of cholecystitis leading to early termination of the study.
Preclinical research indicated that these AEs were offtarget, drug-specific effects and not related to LPA 1 antagonism. Biomarkers of fibrosis or inflammation were improved after treatment with BMS-986020, suggesting potential clinical utility of targeting LPA 1 inhibition. Given the limited treatment options for patients with IPF and the encouraging results in this study, additional research with LPA 1 antagonists is warranted.
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